Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study
N/A
18 Years
70 Years
18 Years
70 Years
Not Enrolling
Female
Breast Cancer
Female
Breast Cancer
Trial Information
Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study
To demonstrate iodide uptake capacity of breast cancer metastases by imaging women with
iodide radioisotope (123I) and calculating potential ablative dose of radioactive iodide
(131I).
Inclusion Criteria:
- Only women diagnosed with breast cancer- 18 years of age or older
- From whom informed consent can be obtained
- Patient is able to provide a fluid (e.g. cyst fluid)
- Patient with blood test that shows protein may allow iodide to accumulate in breast
tissue
- Patient who's breast cancer cells accumulated I123 and held on to it for 24 hours
Exclusion Criteria:- Males
- Children
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Principal Investigator
Irene L. Wapnir
Investigator Role:
Principal Investigator
Investigator Affiliation:
Stanford University
Authority:
United States: Institutional Review Board
Study ID:
BRSMTS0002
NCT ID:
NCT00185809
Start Date:
November 2000
Completion Date:
August 2008
Related Keywords:
- Breast Cancer
- Breast Neoplasms
Name | Location |
|---|---|
| Stanford University School of Medicine | Stanford, California 94305-5317 |
